GRAYMEDY

03 / HEALTH SCIENCE & LONGEVITY

OBSERVATIONAL / EARLY TRANSLATION

October brought a map of immune ageing and a new industry evaluation of a rejuvenation

platform. Prediction and treatment remain separate scientific tasks.

Start with the right ambition

Why measurement matters

The promise of ageing research is more time lived well.

Current profiling requires complex, costly technology.

Immune resilience matters because older people may

The researchers hope the findings could support a

face several health challenges at once, while

simpler blood test. Clinical use would require validation

independence depends on more than a laboratory

in new populations, consistent performance and

measurement. October brought a map of immune-cell

information that adds to routine assessment. An

patterns associated with later health and a programme

unusual immune profile might identify an association

preparing to test an intervention for cellular dysfunction.

without establishing its cause or revealing an effective

These developments highlight the distance between

treatment. Prediction and clinical usefulness are

detecting a biological pattern and demonstrating that

different standards: a test needs to support a decision

changing it improves lives.

that can improve care. [10]

A map, not yet a routine test

A separate attempt to intervene

On 13 October, King's College London described

UCL reported on 8 October that an unnamed

research published in Immunity that analysed about

pharmaceutical company would independently evaluate

12.4 million immune cells from 2,609 mainly healthy

its DoS immune-rejuvenation platform. The

adults across eight cohorts. The work linked different

programme, associated with Alessio Lanna and

balances of granzyme K and granzyme B immune-cell

SenTcell Life, is preparing for first-in-human evaluation.

populations to different ageing trajectories. A granzyme

UCL describes planned early attention to safety and

B-dominant pattern was associated with greater later

biological activity in adults with immune dysfunction.

disease and mortality risk. These are population

The collaboration is a development milestone and a

associations; they do not make an individual's future

sign of commercial interest. It is not a clinical result,

inevitable or show that altering the ratio changes

and the October announcement does not supply

health. [10]

evidence of improved human health or longer life. [11]

06

HEALTH SCIENCE, CLEARLY